<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36064670</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>40</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine.</ArticleTitle><Pagination><StartPage>5835</StartPage><EndPage>5841</EndPage><MedlinePgn>5835-5841</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2022.06.084</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(22)00858-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">To meet the demand for effective and affordable inactivated polio vaccines (IPVs), a reduced dose, aluminium hydroxide (Al(OH)<sub>3</sub>)-adjuvanted IPV vaccine was developed (IPV-Al, Picovax®) and evaluated in clinical trials. The present trial is an extension of two previous trials (a primary and a booster trial). The aim was to evaluate the persistence of seroprotective antibodies (poliovirus type-specific antibody titre ≥ 8) in 4-year-old children who previously received IPV-Al as primary and booster vaccine doses and to determine the potential booster response and safety profile of an additional dose of IPV-Al.</AbstractText><AbstractText Label="METHODS">Children participating in the two previous trials were invited to receive one additional dose of IPV-Al at 4 years of age (2.5 years after the booster dose) and to have their blood samples collected to measure the pre- and post-vaccination antibody titres. Systemic adverse events (AEs) and local reactogenicity were recorded.</AbstractText><AbstractText Label="RESULTS">At study entry, the seroprotection rates were 89.2%, 100% and 91.1% against poliovirus type 1, 2 and 3, respectively. The additional vaccination with IPV-Al boosted the level of poliovirus type 1, 2 and 3 antibodies to above the seroprotection threshold for all but one subject, i.e., 99.4% for type 1 and 100% for types 2 and 3. The additional dose induced a robust booster response of a 26.3-, 13.9- and 30.9-fold increase in titre for poliovirus types 1, 2 and 3, respectively. The vaccine was well tolerated, with only mild and transient AEs reported.</AbstractText><AbstractText Label="CONCLUSIONS">The present trial demonstrated that the primary vaccination with an aluminium-adjuvanted reduced dose IPV induced a persistent immune memory as evidenced by the robust anamnestic response when the subjects were re-exposed to the antigen 2.5 years after the last dose. Thus, the IPV-Al is an efficient and safe addition to increase the availability of inactivated polio vaccines globally. (ClinicalTrials.gov reg no. NCT04448132).</AbstractText><CopyrightInformation>Copyright © 2022. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sáez-Llorens</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Hospital del Niño, Panama City, Panama; Cevaxin, Avenida Mexico Calle 33, Local 4, Panama City, Panama; Sistema Nacional de Investigación, Senacyt, Panama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Milagros</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cevaxin, Avenida Mexico Calle 33, Local 4, Panama City, Panama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeAntonio</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cevaxin, Avenida Mexico Calle 33, Local 4, Panama City, Panama; Sistema Nacional de Investigación, Senacyt, Panama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Torben</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Larix A/S, Lyskær 8b, 2730 Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olesen</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Larix A/S, Lyskær 8b, 2730 Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Jens Søndergaard</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Larix A/S, Lyskær 8b, 2730 Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sørensen</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>AJ Vaccines A/S, Artillerivej 5, 2300 Copenhagen S, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ekstrand</LastName><ForeName>Lena Messerschmidt</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>AJ Vaccines A/S, Artillerivej 5, 2300 Copenhagen S, Denmark. Electronic address: lmek@ajvaccines.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czort</LastName><ForeName>Michaela Katrine</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>AJ Vaccines A/S, Artillerivej 5, 2300 Copenhagen S, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristensen</LastName><ForeName>Hans-Henrik</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>AJ Vaccines A/S, Artillerivej 5, 2300 Copenhagen S, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thulstrup</LastName><ForeName>Niels</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>AJ Vaccines A/S, Artillerivej 5, 2300 Copenhagen S, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christoffersen</LastName><ForeName>Dorte Birk</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>AJ Vaccines A/S, Artillerivej 5, 2300 Copenhagen S, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04448132</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>CPD4NFA903</RegistryNumber><NameOfSubstance UI="D000535">Aluminum</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000535" MajorTopicYN="N">Aluminum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Affordable inactivated polio vaccine</Keyword><Keyword MajorTopicYN="N">Aluminium hydroxide adjuvant</Keyword><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">Oral polio vaccine</Keyword><Keyword MajorTopicYN="N">Polio</Keyword><Keyword MajorTopicYN="N">Reduced dose</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>5</Day><Hour>23</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36064670</ArticleId><ArticleId IdType="pmc">PMC9488130</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2022.06.084</ArticleId><ArticleId IdType="pii">S0264-410X(22)00858-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Initiative GPE. Wild poliovirus list. https://polioeradication.org/polio-today/polio-now/wild-poliovirus-list. Accessed 29 Oct 2021.</Citation></Reference><Reference><Citation>Initiative GPE. Vaccine-Derived Polioviruses. https://polioeradication.org/polio-today/polio-prevention/the-virus/vaccine-derived-polio-viruses/. Accessed 24 Feb 2022.</Citation></Reference><Reference><Citation>Bandyopadhyay A.S., Garon J., Seib K., Orenstein W.A. Polio vaccination: past, present and future. Future Microbiol. 2015;10(5):791–808.</Citation><ArticleIdList><ArticleId IdType="pubmed">25824845</ArticleId></ArticleIdList></Reference><Reference><Citation>Danielsson R., Eriksson H. Aluminium adjuvants in vaccines – a way to modulate the immune response. Semin Cell Dev Biol. 2021;115:3–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33423930</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera L., Pedersen R.S., Peña L., Olsen K.J., Andreasen L.V., Kromann I., et al. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial. Lancet Infect Dis. 2017;17(7):745–753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5483484</ArticleId><ArticleId IdType="pubmed">28454674</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo L.C., Carlos J.C., Gatchalian S.R., Montellano M.E.B., Tabora C., Thierry-Carstensen B., et al. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14weeks and 9months of age. Vaccine. 2020;38:530–538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6983932</ArticleId><ArticleId IdType="pubmed">31703934</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Llorens X., Thierry-Carstensen B., Stoey L.S., Sorensen C., Wachmann H., Bandyopadhyay A.S., et al. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15–18 months. Vaccine. 2020;38:3780–3789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184674</ArticleId><ArticleId IdType="pubmed">32273184</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association Declaration of Helsinki ethical principles for medical research involving human subjects. JAMA. 2000;284:3043–3045.</Citation><ArticleIdList><ArticleId IdType="pubmed">11122593</ArticleId></ArticleIdList></Reference><Reference><Citation>International Council of Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Integrated addendum to ICH E6(1): guideline for good clinical practice E6 (R2). 2016.</Citation></Reference><Reference><Citation>Lindgren L.M., Tingskov P.N., Justesen A.H., Nedergaard B.S., Olsen K.J., Andreasen L.V., et al. First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age. Vaccine. 2017;35(4):596–604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5267481</ArticleId><ArticleId IdType="pubmed">28027810</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897268</ArticleId><ArticleId IdType="pubmed">20463105</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown G.C., Rabson A.S., Schieble J.H. The effect of gamma globulin on sub clinical infection in familial associates of poliomyelitis cases. II. Serological studies and virus isolations from pharyngeal secretions. J Immunol. 1955;74:71–80.</Citation><ArticleIdList><ArticleId IdType="pubmed">13233522</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson S. Module 6: Poliomyelitis. https://www.who.int/ihr/polio1993en.pdf. Accessed 03 Nov 2021.</Citation></Reference><Reference><Citation>Bergfors E., Hermansson G., Nyström Kronander U., Falk L., Valter L., Trollfors B. How common are long-lasting, intensely itching vaccination granulomas and contact allergy to aluminium induced by currently used pediatric vaccines? A prospective cohort study. Eur J Pediatr. 2014;173(10):1297–1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">24752308</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>